Jaguar Health Announces Preliminary Clinical Trial Results for Crofelemer in Short Bowel Syndrome
I'm PortAI, I can summarize articles.
Jaguar Health Inc. announced preliminary results from a clinical trial of crofelemer for short bowel syndrome with intestinal failure. An abstract has been submitted for the Digestive Disease Week® conference in May 2026. Crofelemer has Orphan Drug Designation from the FDA and EMA. Additional trials are ongoing. This information is for informational purposes only and not financial advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments